Craft
Gracell

Gracell

Preclinical Phase Products

1

Q3, 2020

Revenue

¥366 K

FY, 2021

Market Capitalization

$140.4 M

2022-09-19

Gracell Summary

Company summary

Overview
Gracell Biotechnologies is a clinical-stage biotech company developing cell gene therapies for cancer. It focuses on leukemia, lymphoma, myeloma, and solid tumors.
Type
Public
Founded
2017
HQ
Suzhou, CN | view all locations
Website
https://www.gracellbio.com/
Cybersecurity rating
Sectors

Key people

  • William Wei Cao

    William Wei Cao, Founder, Chairman, and Chief Executive Officer

  • Martina A. Sersch

    Martina A. Sersch, Chief Medical Officer

    • Kevin Yili Xie

      Kevin Yili Xie, Chief Financial Officer

      • Yili Kevin Xie

        Yili Kevin Xie, Chief Financial Officer

      Operating MetricsView all

      Preclinical Phase Products

      1

      Q3, 2020

      Phase I Trials Products

      4

      Q3, 2020

      LocationsView all

      2 locations detected

      • Suzhou, Jiangsu Sheng HQ

        China

        Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park

      • Shanghai Shi

        China

        12th floor, 926 Yishan Rd, Xuhui Qu

      Gracell Financials

      Summary financials

      Net income (Q2, 2022)
      (¥146.3M)
      Cash (Q1, 2022)
      ¥1.6B
      EBIT (Q2, 2022)
      (¥144.0M)
      Enterprise value
      ($1.2B)

      Footer menu